Le Lézard
Classified in: Health, Business
Subject: CXP

Siemens Healthineers Announces the Expansion of Ottawa Manufacturing Facility


OAKVILLE, ON, Oct. 11, 2018 /CNW/ - Siemens Healthineers has announced that its Ottawa, Ontario manufacturing facility that manufactures the epoc® blood analysis system will be expanded by 5000 square feet to support new manufacturing lines and accommodate growth of the healthcare business worldwide and in Canada.

Siemens Healthineers (CNW Group/Siemens Healthineers)

The epoc system is a handheld, wireless solution that enables comprehensive blood analysis testing at the patient's side on a single room-temperature test card, with results in less than a minute.

"This investment is a critical step toward enabling the growth of our medical technology business in Canada and Ontario by ensuring we have the manufacturing capacity in place to support continued development," said Eric LaFleche, General Manager of Siemens Healthineers in Canada. "We are proud that the skills and experience of staff are recognized, and Canada continues to be known for its technology, skills, and favourable innovative business environment."

The 5000 square-foot expansion is expected to be complete by June 2021, and will complement the company's other point-of-care operations in the United States, United Kingdom, and India.

The point-of-care testing portfolio from Siemens Healthineers includes several solutions designed to provide immediate, convenient, and easy-to-use diagnostic testing. From the emergency department to the physician's office, clinical management decisions can be made immediately and result in improved patient safety, clinical outcomes, and overall patient satisfaction. The Ottawa facility is focused on the manufacture of the epoc blood analysis system, which provides critical caregivers with real-time, laboratory quality test results at the patient's bedside.

The epoc blood analysis system can be used for a wide range of tests including: blood gas, which measures the amount of oxygen and carbon dioxide in the blood that can indicate the presence of certain medical conditions such as kidney disease, heart failure, diabetes, hemorrhage, chemical poisoning, a drug overdose, or shock, among others; electrolytes and metabolytes, which indicate kidney health, blood sugar levels, and levels of electrolytes such as potassium and sodium; lactate that tests for sepsis; creatinine, which indicates kidney function; and blood urea nitrogen that reveals information about how well the kidneys and liver are functioning.

More information on the Siemens Healthineers epoc blood analysis system is available online.

Follow us on Twitter at: https://twitter.com/SiemensHealth

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of ?13.7 billion and adjusted profit of ?2.5 billion and has about 48,000 employees worldwide. Further information is available at www.siemens-healthineers.com.

SOURCE Siemens Healthineers


These press releases may also interest you

at 15:24
ImaginAb, Inc., a clinical stage immuno-oncology imaging company, today announces that it will attend and present at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held June 22-25, 2019, at the Anaheim...

at 15:20
Versiti Blood Research Institute, a national leader in blood health innovation, has been awarded a 5-year, $13.2 million grant from the National Institutes of Health (NIH) to continue its research into von Willebrand disease (VWD), both the most...

at 15:15
The "Biomaterials Market by Type of Materials (Metallic, Ceramic, Polymers, Natural) & By Application (Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Neurological disorders, Tissue Engineering, Ophthalmology) -Global Forecast to...

at 15:15
The "Global Optogenetics Market Growth, Trends, and Forecasts (2019-2024)" report has been added to ResearchAndMarkets.com's offering. The major factors for the growth of the optogenetics market include the potential diagnostic tool in the field of...

at 15:15
Columbia Care Inc. ("Columbia Care" or the "Company") (NEO: CCHW, OTC: COLXF), one of the largest global operators in the medical cannabis industry, with licenses in 15 jurisdictions in the US and the EU, today announced the initiation of a research...

at 15:14
Pomerantz LLP is investigating claims on behalf of investors of Intersect ENT, Inc. ("Intersect" or the "Company") . Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation...



News published on 11 october 2018 at 11:50 and distributed by: